| Background: | Members of the S100 family are low molecular mass acidic proteins characterized by cell-type-specific expression and the presence of EF-hand Ca2+-binding domains. One of the least studied members of the S100 family is S100P, a 95-amino acid protein first purified from placenta with a restricted cellular distribution. The molecular structure of S100P has been well described and supports its classification in the S100 family of proteins. Expression of S100P has been noted in esophageal epithelial cells during their differentiation, indicating that it may play a role in normal development. There is also considerable evidence that S100P plays a role in cancer. S100P expression has been noted in various cancer cell lines including breast cancer, where it was associated with cellular immortalization, and colon cancer, where its expression was elevated in doxorubicin-resistant cells. S100P has also been shown to be expressed in tumors, including prostate cancer, where its expression is androgen-sensitive, and pancreatic adenocarcinoma, where expression has been localized to the neoplastic epithelium of pancreatic. Furthermore, S100P expression has been shown to be correlated with decreased survival in patients with lung cancer. |
| Regulatory Statement: | For Research Use Only. Not for use in diagnostic procedures. |
| Product Type: | Protein |
| Shipping: | dry ice |
| Size: | 100 μg |
| Species Reactivities: | Human |
| Status: | RUO |
| Storage: | -70℃ |
| Target: | S100P |
Applications:
There are no references for CircuLex Human S100P Low Endotoxin at this time.
